8 results
Guillain-Barre Syndrome - Summary

Acute AIDP that presents with rapidly progressive flaccid weakness

Epidemiology:
 • 1-2 cases/100,000 per
COVID 19 - Zika virus ... Clinical Features ... • Weakness: Starts ... Diagnosis: • ... #management #treatment
Myasthenia Gravis Overview

Myasthenia Gravis is an autoimmune disorder of the postsynaptic neuromuscular junction.  Ab to
life-threatening Differential ... myasthenia Diagnosis ... stimulation - Single fiber ... immunologic assay - MuSK ... #diagnosis #management
Myasthenia Gravis - Summary
 • an autoimmune disease of the postsynaptic neuromuscular junction associated with antibodies
Myasthenia Gravis ... : • Based on clinical ... - Improves clinical ... #Myasthenia #Gravis ... #diagnosis #management
Guillain-Barré Syndrome (GBS)
Acute autoimmune demyelinating polyradiculoneuropathy that presents with rapidly progressive flaccid weakness
Epidemiology:
 • Incidence: 1
Guillain-Barré Syndrome ... (HIV), and Zika ... transplantation CLINICAL ... and cauda equina TREATMENT ... #management #neurology
Immune Reconstitution Inflammatory Syndrome - Overview of IRIS

What Is IRIS?
	• A state of hyperinflammatory response that
noncompliance • Clinical ... initiation Clinical ... Leishmaniasis Differential ... Inflammatory #Syndrome #Differential ... #Diagnosis #Management
BEE Syndromes - Non-inflammatory Causes

Immune-mediated conditions affecting the Brain, Eye, and Ear

Visual or auditory symptoms in
and treatment can ... MRI lesions and clinical ... consistent with MS ... noninflammatory #differential ... #diagnosis
Transverse Myelitis Overview

Focal inflammatory disorder of the spinal cord resulting in rapid onset of weakness, sensory
Transverse Myelitis - Clinical ... , HIV, Hep A/B/CMV ... Transverse Myelitis Treatment ... #management #neurology ... #differential
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
salivary ducts Clinical ... system: small-fiber ... phenomenon (16%) MSK ... Adenocarcinoma Treatment ... #Management